论文部分内容阅读
[目的]:观察胃力康配合奥美拉唑三联疗法治疗幽门螺杆菌(Hp)阳性消化性溃疡的疗效。[方法]选取2012年1月~2014年1月期间我院接收治疗的108例幽门螺杆菌阳性消化性溃疡患者。采用随机数表法将108例患者分为观察组和对照组,各54例。2组患者均给予20mg奥美拉唑+1.0g阿莫西林+0.5g克拉霉素进行治疗,疗程为2周。观察组患者加服10g胃力康,疗程为4周。对比2组患者的临床疗效、症状缓解率、药物不良反应上报率、Hp根除率及6个月后溃疡复发情况。[结果]观察组患者的临床总有效率为95.28%显著高于对照组患者的81.49%,比较2组间差异具有统计学意义(P<0.05)。2组患者治疗后腹胀、腹痛、反酸、嗳气、恶心等症状的缓解病例数与缓解率比较差异无统计学意义(P>0.05)。观察组患者治疗后Hp根除率及6个月后溃疡复发率分别为94.44%、3.70%,对照组患者治疗后Hp根除率及6个月后溃疡复发率分别为81.48%、11.11%,比较2组间差异有统计学意义(P<0.05)。观察组患者治疗后药物不良反应上报率为7.40%较对照组患者的9.25%差异无统计学意义(P>0.05)。[结论]胃力康配合奥美拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡的临床疗效肯定且复发率较低,可以在临床上进一步推广和使用。
[Objective] To observe the curative effect of Weili Kang combined with omeprazole triple therapy on Helicobacter pylori (Hp) -positive peptic ulcer. [Methods] A total of 108 patients with H. pylori-positive peptic ulcer admitted to our hospital from January 2012 to January 2014 were selected. 108 cases were divided into observation group and control group using random number table method, each 54 cases. Patients in both groups were given 20 mg omeprazole plus 1.0 g amoxicillin plus 0.5 g clarithromycin for 2 weeks. Observation group patients plus service 10g Wei Li, treatment for 4 weeks. The clinical efficacy, symptom relief rate, adverse drug reaction rate, Hp eradication rate and the recurrence of ulcer after 6 months were compared between the two groups. [Results] The total effective rate of observation group was 95.28%, which was significantly higher than that of control group (81.49%). The difference between the two groups was statistically significant (P <0.05). There was no significant difference between the two groups in the number of relieved cases and the remission rate of abdominal distension, abdominal pain, acid reflux, belching, nausea and other symptoms after treatment (P> 0.05). The Hp eradication rate and the ulcer recurrence rate in the observation group after treatment were 94.44% and 3.70% respectively. The Hp eradication rate and the ulcer recurrence rate after 6 months in the control group were 81.48% and 11.11%, respectively, compared with 2 There was significant difference between groups (P <0.05). In the observation group, the reported rate of ADR was 7.40% after treatment compared with 9.25% in the control group (P> 0.05). [Conclusion] Wei Li Kang combined with omeprazole triple therapy for the treatment of Helicobacter pylori-positive peptic ulcer clinical efficacy and a low recurrence rate, which can be further promoted and used clinically.